Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT06655519
What this trial is testing

An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia
Peking University People's Hospital 12
Testing effectiveness (Phase 2)Looking for participantsNCT04271644
What this trial is testing

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Who this might be right for
Multiple MyelomaNeoplasm, Plasma CellMultiple Myeloma in Relapse
Chongqing Precision Biotech Co., Ltd 80
Very early researchLooking for participantsNCT06732232
What this trial is testing

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Who this might be right for
RelapsedRefractoryMultiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd 12
Early research (Phase 1)Enrolling By InvitationNCT05650749
What this trial is testing

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

Who this might be right for
Refractory NeuroblastomaRelapsed NeuroblastomaHigh-risk Neuroblastoma+2 more
Stephan Grupp MD PhD 45
Very early researchUnknownNCT03060343
What this trial is testing

Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Yu Fenglei 10
Testing effectiveness (Phase 2)WithdrawnNCT04029038
What this trial is testing

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Who this might be right for
CD19 PositiveCD22 PositiveMinimal Residual Disease+7 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)UnknownNCT05143151
What this trial is testing

CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer

Who this might be right for
Advanced Pancreatic Carcinoma
Shenzhen University General Hospital 10
Early research (Phase 1)WithdrawnNCT02439788
What this trial is testing

3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA

Who this might be right for
Neuroblastoma
Baylor College of Medicine
Testing effectiveness (Phase 2)Study completedNCT01454596
What this trial is testing

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Who this might be right for
Malignant GliomaGlioblastomaBrain Cancer+1 more
National Cancer Institute (NCI) 18
Early research (Phase 1)UnknownNCT05783570
What this trial is testing

To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307

Who this might be right for
Advanced Hepatocellular Carcinoma
Eutilex 12
Early research (Phase 1)Not Yet RecruitingNCT07432100
What this trial is testing

Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaChimeric Antigen Receptor T-cellUniversal CLL1 CAR-T
Mingfeng Zhao 20
Testing effectiveness (Phase 2)Looking for participantsNCT04440436
What this trial is testing

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

Who this might be right for
NHL
Beijing Immunochina Medical Science & Technology Co., Ltd. 52
Early research (Phase 1)UnknownNCT03344367
What this trial is testing

Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
Peking University 20
Early research (Phase 1)Active Not RecruitingNCT02735083
What this trial is testing

Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19

Who this might be right for
Advanced Lymphoid Leukemia
Institut de Recherches Internationales Servier 28
Testing effectiveness (Phase 2)Looking for participantsNCT07288879
What this trial is testing

DALY II Japan/MB-CART2019.1 for DLBCL

Who this might be right for
DLBCL - Diffuse Large B Cell LymphomaCAR T Cell Therapy
Miltenyi Biomedicine GmbH 31
Testing effectiveness (Phase 2)Looking for participantsNCT07584889
What this trial is testing

Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

Who this might be right for
B Cell LymphomaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia
Shenzhen University General Hospital 10
Testing effectiveness (Phase 2)Study completedNCT03792633
What this trial is testing

Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

Who this might be right for
Acute Lymphoblastic Leukemia
University of Pennsylvania 106
Early research (Phase 1)Looking for participantsNCT06688435
What this trial is testing

Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis

Who this might be right for
Myasthenia Gravis
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 60
Early research (Phase 1)Looking for participantsNCT05805371
What this trial is testing

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
City of Hope Medical Center 21
Testing effectiveness (Phase 2)Looking for participantsNCT04776330
What this trial is testing

A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Who this might be right for
Multiple MyelomaNeoplasm, Plasma CellMultiple Myeloma in Relapse
Chongqing Precision Biotech Co., Ltd 80
Next Page